Kuur TherapeuticsProduct Overview

Our Pipeline

Therapy Type
Product
Target Tumors
Target Antigens
Preclinical
Phase 1
Phase 2 & 3
Upcoming Milestones
Autologous
KUR-501
Neuroblastoma
GD2
Neuroblastoma interim clinical update May 2020
Allogeneic
KUR-502
Hematological malignancies
CD19
First patient treated 1H 2020
Allogeneic
KUR-503
Liver cancer
GPC3
Proof of concept for clinical construct 2H 2020
KUR-501: Autologous

We are developing a GD2-CAR NKT autologous product (KUR-501) for the treatment of neuroblastoma. A first-in-human study is underway at Baylor College of Medicine (BCM) at Texas Children’s Hospital in Houston, TX.

CAR-NKT in Relapsed or Refractory High Risk GD2+ Neuroblastoma
KUR-501 CAR-NKT Therapy
  • Autologous CAR-NKT cells targeting GD2
  • Cells engineered to express IL-15 to improve persistence and efficacy
GD2 Biology and Tumor Expression
  • Clinically validated target widely expressed on neuroblastoma cells
  • Limited expression on normal tissue
Unmet Medical Need
  • Neuroblastoma causes almost 15% of childhood cancer related deaths
  • Over half of all children with neuroblastoma have high risk disease
  • No standard therapy for patients with R/R high risk neuroblastoma
  • R/R high risk disease patients have a poor prognosis
    • Median survival of 1-3 years
Clinical Development Plan
  • Preclinical evaluation in SCLC, malignant melanoma & other indications
KUR-502: Allogeneic

We are developing an off-the-shelf CD19 targeted allogeneic CAR-NKT product for the treatment of relapsed, refractory CD19-positive malignancy.

Off-the-Shelf CAR-NKT in Relapsed or Refractory CD19+ Malignancies
KUR-502 CAR-NKT Therapy
  • Allogenic CAR-NKT cells targeting CD19
  • Cell engineering to:
    • Express IL-15 to improve persistence and efficacy
    • Down-regulate MHC modules and diminish allo-reacitvity
CD19 Biology and Tumor Expression
  • Clinically validated target expressed on B cells and related malignancies
  • On target tissue tumor toxicity limited to B cell aplasia
Unmet Medical Need
  • Autologous CAR-T products have complicated logistics which can lead to treatment delays
  • Bridging chemotherapy required during product manufacturing
  • Autologous CAR-T product quality can be highly variable
Clinical Development Plan
  • First patient expected to be treated in Phase 1 trial in 1H 2020
  • Evaluating safety, cell expansion and initial signs of therapeutic activity
KUR-503: Allogeneic

We are developing an off-the-shelf GPC3 targeted allogeneic CAR-NKT product for the treatment of advanced hepatocellular (liver) cancer.

Off-the-Shelf CAR-NKT Cell Therapy of Hepatocellular Carcinoma (HCC)
KUR-503 CAR-NKT Therapy
  • Allogeneic CAR-NKT cells targeting GPC3
  • Cells engineered to:
    • Express IL-15 to improve persistence and efficacy
GPC3 Biology and Tumor Expression
  • Transmembrane heparan sulfate proteoglycan (Glypican-3)
  • Expressed on the majority (>70%) of HCC tumors
  • May play a role in HCC tumor progression
  • Antibodies against GPC3 active in phase 1
  • No expression on normal hepatic tissue
  • Expressed on very limited adult tissue at low levels
  • Expressed on placenta and some fetal tissue
Unmet Medical Need
  • Multiple agents approved for 1st or 2nd line advanced HCC but response rates are generally <20% and overall survival generally < 1 year
GPC3 Expression in HCC (Diffuse and Membranous Patterns)

GPC3 expression in HCC(diffuse and membranous patterns)